Skip NavigationSkip to Content
Return Return to Search Results

Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer

  1. Author:
    El Abdaimi, K.
    Papavasiliou, V.
    Rabbani, S. A.
    Rhim, J. S.
    Goltzman, D.
    Kremer, R.

  2. Author Address

    Kremer R Royal Victoria Hosp, Calcium Res Lab, Dept Med H4-67,687 Pine Ave W Montreal PQ H3A 1A1 Canada Royal Victoria Hosp, Calcium Res Lab, Dept Med Montreal PQ H3A 1A1 Canada McGill Univ, Dept Med Montreal PQ H3A 1A1 Canada NCI, Mol Oncol Lab Frederick, MD 21702 USA
    1. Year: 1999
  2. Journal: Cancer Research
    1. 59
    2. 14
    3. Pages: 3325-3328
  4. Type of Article: Article
  1. Abstract:

    EB1089, an analogue of 1,25 dihydroxyvitamin D with low calcemic activity is a potent inhibitor of parathyroid hormone-related peptide (PTHRP) production in vitro. The purpose of the present study was to determine whether EB1089 could reverse established hypercalcemia in BALE C nude mice implanted s.c. with a human epithelial cancer previously shown to produce high levels of PTHRP in vitro. Total plasma calcium was monitored before and after tumor development and increased steadily when the tumor reached greater than or equal to 0.5 cm(3). When total calcium was greater than or equal to 2.85 mmol/liter, animals were treated with a constant infusion of EB1089 or vehicle alone for a period of 2 weeks. A significant and sustained reduction of plasma calcium from 3.2 +/- 0.1 to 2.7 +/- 0.08 (P < 0.01) mmol/liter was observed during infusion with EB1089. In contrast, calcium levels in vehicle-treated animals continued to rise during the infusion period, Tumor growth velocity also slowed significantly after the administration of EB1089 as compared with vehicle-treated animals. Plasma PTHRP levels measured at the end of the 2 weeks' infusion period were significantly lower in animals treated with EB1089 as compared with animals treated with vehicle alone (44 +/- 8 pg/ml versus 194 +/- 35 pg/ml, P < 0.001). These results, therefore, demonstrate that EB1089 can reverse established hypercalcemia in a human model of squamous cancer. [References: 37]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel